UCHL1 acts as a potential oncogene and affects sensitivity of common anti-tumor drugs in lung adenocarcinoma

Jianbo Yao1†, Abdusemer Reyimu2†, Ao Sun3†, Zaxi Dujio4, Wubi Zhou5, Song Liang6, Suxia Hu7, Xiang Wang8*, Jingjing Dai9* and Xiaoguang Xu4*

Abstract

Background: Lung adenocarcinoma is the leading cause of cancer death worldwide. Recently, ubiquitin C-terminal hydrolase L1 (UCHL1) has been demonstrated to be highly expressed in many tumors and plays the role of an oncogene. However, the functional mechanism of UCHL1 is unclear in lung adenocarcinoma progression.

Methods: We analyzed the differential expression of the UCHL1 gene in lung adenocarcinoma and normal lung tissues, and the correlation between the UCHL1 gene and prognosis was also analyzed by the bioinformatics database TCGA. Meanwhile, we detected and analyzed the expression of UCHL1 and Ki-67 protein in a tissue microarray (TMA) containing 150 patients with lung adenocarcinoma by immunohistochemistry (IHC) and clinicopathological characteristics by TCGA database. In vitro experiments, we knocked down the UCHL1 gene of A549 cells and detected the changes in cell migration, invasion, and apoptosis. At the same time, we analyzed the effect of UCHL1 on anti-tumor drug sensitivity of lung adenocarcinoma by a bioinformatics database. In terms of the detection rate of lung adenocarcinoma indicators, we analyzed the impact of UCHL1 combined with common clinical indicators on the detection rate of lung adenocarcinoma through a bioinformatics database.

Results: In this study, the analysis of UCHL1 protein expression in lung adenocarcinoma proved that obviously higher UCHL1 protein level was discovered in lung adenocarcinoma tissues. The expression of UCHL1 was closely related to poor clinical outcomes. Interestingly, a significantly positive correlation between the expression of UCHL1 and Ki-67-indicated UCHL1 was associated with tumor migration and invasion. Through executing loss of function tests, we affirmed that silencing of UCHL1 expression significantly inhibited migration and invasion of lung adenocarcinoma cells in vitro. Furthermore, lung adenocarcinoma cells with silenced UCHL1 showed a higher probability of apoptosis.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
In terms of the detection rate of lung adenocarcinoma indicators, we discovered UCHL1 could improve the detection rate of clinical lung adenocarcinoma and affect drug sensitivity.

**Conclusion:** In lung adenocarcinoma, UCHL1 promotes tumor migration, invasion, and metastasis by inhibiting apoptosis and has an important impact on the clinical drug treatment of lung adenocarcinoma. In addition, UCHL1 can improve the detection rate of clinical lung adenocarcinoma. Above all, UCHL1 may be a new marker for the diagnosis of lung adenocarcinoma and provide a new target for the treatment of clinical diseases.

**Introduction**
Lung adenocarcinoma is a fatal disease, which happens frequently around the world [1]. Great progress has been made in the treatment of lung adenocarcinoma [2], such as surgical resection [3], ablation [4], and targeted therapy [5] in the last 20 years. So far, the most effective treatment to cure early lung adenocarcinomas is surgical treatment [6]. Nevertheless, as a result of tumor recurrence and metastasis, the survival rate of lung cancer (22%) in the recent 5 years is not optimistic [7]. Thus, it is necessary to deeply study the molecular mechanism of the occurrence and development of lung adenocarcinoma, find new effective treatment methods, and reduce the recurrence rate of lung adenocarcinoma.

Ubiquitin C-terminal hydrolase-L1 (UCHL1), which is usually expressed in the nerve cells and testicles, is a neuroendocrine cell-specific product with the role of scavenging ubiquitin protein [8]. Although UCHL1 is expressed in normal tissues such as neurons, more and more evidence suggests that UCHL1 is upregulated in some human cancers [9] and plays a critical role in cell proliferation, migration, invasion, and anti-apoptosis [10]. Moreover, neurodegeneration [11], cancer [12], and fibrosis [13] are closely related to the disorder of UCHL1 expression. However, the role of UCHL1 remains unclear in lung adenocarcinoma.

Thus, our study aimed to investigate the expression level of UCHL1 in lung adenocarcinoma and its regulatory effect on drug sensitivity and detection rate of lung adenocarcinoma. The purpose of this study was to investigate the mechanism of UCHL1 in lung adenocarcinoma cells by silencing the UCHL1 gene.

Currently, we have found that UCHL1 is associated with poor prognosis by bioinformatics analysis. Immunohistochemical analysis showed that the expression of UCHL1 was positively correlated with Ki-67 and promoted tumor proliferation. Moreover, we found that UCHL1 can promote the migration and invasion of tumor cells in the functional gene knockout experiment and has an important impact on the clinical drug treatment of lung adenocarcinoma. In addition, UCHL1 can improve the detection rate of clinical lung adenocarcinoma. Our results suggested that UCHL1 may be a target for the diagnosis and treatment of lung adenocarcinoma.

**Materials and methods**

**Bioinformatics analysis**
In order to explore the expression of UCHL1 in lung adenocarcinoma and normal tissues, the expression of UCHL1 was detected in the UALCAn database (http://ualcan.path.uab.edu/analysis.html). The search criteria are as follows: (1) gene symbol: UCHL1; (2) TCGA dataset: lung adenocarcinoma; and (3) links for analysis: expression. The analysis of UCHL1 gene expression, $P < 0.05$, for the difference was statistically significant. Kaplan-Meier plotter online analysis tool was used to analyze the correlation between UCHL1 and overall survival (OS) in patients with lung adenocarcinoma. The search criteria are as follows: (1) gene symbol: UCHL1; (2) split patients by auto select best cutoff; (3) survival: OS; and (4) histology: adenocarcinoma. To explore the relationship between UCHL1 expression and clinicopathological features in lung adenocarcinoma, we downloaded RNA sequence data and clinical information of 483 patients with complete clinical data from TCGA database. The $c^2$ test was used to analyze the relationship between UCHL1 expression and clinical parameters of patients with lung adenocarcinoma. Then, the receiver operating characteristic (ROC) curve was used to analyze the accuracy of UCHL1 combined with common clinical indicators (ALK, EGFR, TTF1) in the diagnosis of lung adenocarcinoma. RNAactDrug is a comprehensive database of RNAs related to drug sensitivity obtained from multi-omics data. In this study, RNAactDrug was used to predict anticancer drugs associated with UCHL1.

**Tissue microarrays (TMAs) of lung adenocarcinoma**
According to the hematoxylin-eosin (HE) staining results of each lung adenocarcinoma tissue section, 150 cases of cancer tissue and normal lung tissue were determined. The micro tissue sampling equipment was used to conduct micro-sampling on the determined tissues, which were arranged in the carrier tank in turn, and liquid paraffin was slowly injected until the tissues were completely coated. After cooling at 4 °C overnight, the chip wax block was finished. Determine whether the quality meets the requirements through the HE re-staining results of TMAs slices. All research experiments involving patient
data were approved by the Ethics Committee (approval number: YX-2021-074-01).

**Immunohistochemical analysis**

Immunohistochemistry was used to detect the expression of UCHL1 in lung adenocarcinoma. The slices were placed in an oven at 60 °C for 20 min. After removal, the slices were soaked in xylene solution twice for 10 min and then soaked in 100%, 95%, 90%, and 80% ethanol for 5 min. After cleaning with PBS solution, the slices were incubated in 3% hydrogen peroxide for 20 min and then washed with PBS solution. After drying, the normal goat serum was dripped into the slice surface and incubated at 37 °C for 30 min. The primary antibody (UCHL1/#13179 cell signaling technology, Ki-67/ab15580 abcam) was taken out and added into the wet box at 4 °C overnight. After washing with PBS, the labeled second antibody was added and incubated at 37 °C for 30 min. Then, PBS was washed again and added with a chromogenic agent for routine re-staining, dehydration, and transparency. Finally, neutral gum was used to seal the slices, and the color development intensity was observed under the microscope.

**Immunocytochemistry**

The cells were cultured on the cover glass, washed slowly with phosphate-buffered saline (PBS), and fixed with formaldehyde solution. The cells were then washed with PBS buffer, infiltrated with 0.1% Triton X-100, cultured in a closed solution, and incubated with UCHL1 antibody at 4 °C for 12 h. After washing with PBS, the labeled second antibody was added and incubated at 37 °C for 30 min. Then, PBS was washed again and added with a chromogenic agent for routine re-staining, dehydration, and transparency. Finally, neutral gum was used to seal the slices, and the color development intensity was observed under the microscope.

**Cell line cultivation**

A549 cells were donated by the medical school of Anhui University of Science and Technology. The DMEM medium was used to culture cells, and 100 U/ml penicillin, 10% fetal bovine serum, and 100 mg/ml streptomycin were added. The humidified incubator was set at 37 °C, and the concentration of carbon dioxide was 5%.

**Construction of UCHL1 gene knockout cells**

LDN-57444 (LDN, abcam 141487), UCHL1 inhibitor, was used to inhibit the expression of UCHL1 protein in A549 cells. Normal A549 cells were used as a negative control. \(5 \times 10^6\) cells were cultured in each well of six-well plate using a DMEM medium containing 10% FBS until the fusion degree was about 80%. After the cells were cultured in a serum-free medium overnight, LDN was added to the medium to make the final concentration of the drug 10 mm. After 36 h of

---

**Fig. 1** Overexpression of UCHL1 mRNA is associated with survival time in lung adenocarcinoma. **A** UCHL1 mRNA expression in normal and lung adenocarcinoma tissues from TCGA datasets. **B** Kaplan-Meier curve showing overall survival of patients (in percentage) with lung adenocarcinoma, stratified by UCHL1 expression (high- and low-scoring tumors)
drug stimulation, the test of knockout effect was carried out.

Migration and invasion test
As for the cell migration experiment, $5 \times 10^6$ cells were cultured in each well of six-well plate using a DMEM medium containing 10% FBS until the fusion degree was about 80%. After the cells were cultured in a serum-free medium overnight, they were scratched with a 200-ml suction tip, and the results were observed every day. For the cell invasion experiment, there was no serum in the DMEM medium, and $1 \times 10^5$ cells were suspended in the medium. Cells were placed in the cavity of the insertion chamber of the matrix gel coated with a diameter of 8 mm, and the DMEM medium containing 10% FBS was used as a chemical attractant to fill the cavity. Forty-eight hours later, the cells invading the lower surface were fixed with an appropriate concentration of methanol and finally stained for microscopic examination.

Detection of apoptosis by flow cytometry
The materials required for the experiment are as follows: 5 ml and 10 ml graduated pipettes, 5 to 1000 μl adjustable single channel micropipettes with disposable tips, beakers, flasks, cylinders necessary for the preparation of reagents glass-distilled or deionized water, benchtop centrifuge, flow cytometer, and annexin V-FITC apoptosis detection kit. The cells were washed with PBS by gently shaking or pipetting up and down. The cells were resuspended in 200 μI binding buffer (1 x); The cell density was $4 \times 10^6/\mu l$. Five microliters annexin V-FITC was added to the 195-μl cell suspension. The cells were mixed and incubated at room temperature for 10 min. The cells were washed in 200 μl binding buffer (1 x) and resuspended in 190 μl binding buffer (1 x). Then, 10 μl propidium iodide (20 μg/ml) was added. Finally, flow cytometry analysis was carried out.

Western blot
The cells were extracted and lysed in the RIPA lysis buffer. The target protein was obtained by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the protein samples separated by electrophoresis were transferred onto the polyvinylidene fluoride (PVDF) membrane. The PVDF membrane coated with the target protein reacted with the specific antibody (UCHL1/#13179 cell signaling technology, Ki-67/ab15580 abcam) and then incubated with the labeled second antibody (KGAA35/37). The results were observed after adding the reaction substrate.

Statistical analysis
Graphpad prism 7.0 was used for statistical analysis. Analysis of variance, $t$-test, $c^2$ test, and Dunnett multiple comparison were used to analyze the data. When $p$-value was less than 0.05, there was dramatic difference.

Results
UCHL1 expression correlated with prognosis and poor clinical outcomes in lung adenocarcinoma patients
To prove the correlation between UCHL1 expression and human disease, through TCGA bioinformatics database analysis, we found that there was a significant difference in the expression of UCHL1 between lung adenocarcinoma and normal lung tissue ($^{*P} < 0.05$, Fig. 1A, Table 1), and the survival rate of patients with high expression of UCHL1 was significantly lower than that of patients with low expression of UCHL1 (Fig. 1B). Meanwhile, we used a human lung adenocarcinoma TMA for UCHL1 protein expression (Fig. 2A) and revealed that the expression of UCHL1 was lower in the adjacent normal tissues, but higher in the malignant tissues of lung adenocarcinoma patients (Fig. 2B). We aimed to distinguish the differential compartmentalization of UCHL1 expression in tumors

Table 1
| Factors | Number of cases (n) | UCHL1 expression | $c^2$ | P |
|---------|-------------------|-----------------|------|---|
| Sex     |                   | Low (n = 241)   | High (n = 242) |
| Male    | 223               | 97              | 126             |
| Female  | 260               | 144             | 116             |
| Age (years) |              |                 |                 |
| < 60    | 131               | 59              | 72              |
| ≥ 60    | 352               | 182             | 170             |
| T       |                   | 0               | 1               |
| T1–2   | 418               | 209             | 209             |
| T3–4   | 62                | 31              | 31              |
| Tx      | 3                 |                 |                 |
| N       |                   |                 |                 |
| N0      | 312               | 163             | 149             |
| N1–3   | 161               | 75              | 86              |
| Nx      | 10                |                 |                 |
| M       |                   |                 |                 |
| MD      | 319               | 154             | 165             |
| M1      | 25                | 8               | 17              |
| Mx      | 139               |                 |                 |
| Stage  |                   |                 |                 |
| I–II   | 378               | 191             | 187             |
| III–IV | 105               | 50              | 55              |

Analyses were performed using the $c^2$ test
Tx the primary tumor cannot be determined, Nx unable to evaluate, Mx unable to evaluate

$^{*P} < 0.05$
with respect to the frequency of UCHL1 expression in cancer cells. The IHC scores indicated that UCHL1 was upregulated in the tumor tissue compared with the normal tissues (Fig. 2B). Further analysis supported that the expression of UCHL1 was positively correlated with Ki-67 (Fig. 2C, D), and Ki-67 was positively correlated with cell proliferation. Moreover, UCHL1 expression was positively correlated with poor clinical survival of patients with lung adenocarcinoma (Fig. 1B). In a word, the above results illustrated that UCHL1 was upregulated and would be a diagnostic indicator for patients with lung adenocarcinoma.

**Knockdown of UCHL1 inhibited lung adenocarcinoma cells migration and invasion**

In order to prove the role of UCHL1 in the metastasis of lung adenocarcinoma, we used the classical scratch and Transwell method to detect the influence of UCHL1 on the migration and invasion of lung adenocarcinoma cells. The results showed that the migration and invasion of lung adenocarcinoma cells were significantly reduced with the silencing of UCHL1 (Fig. 3).

**UCHL1 enhanced cell survival by reducing apoptosis**

Flow cytometry showed that normal living cells were not stained with annexin V-FITC and propidium iodide (bottom left). The early apoptotic cells were only stained by annexin V-FITC, but not by propidium iodide (bottom right). The necrotic cells and the late apoptotic cells could be stained with annexin V-FTTC and propidium iodide (top right). The upper left part of the figure shows the detection error within the allowable range. In Fig. 4, when the UCHL1 of lung adenocarcinoma cells was silenced, cell apoptosis was significantly enhanced (**P < 0.01).

**UCHL1 affects the sensitivity of commonly used anti-tumor drugs**

RNAactDrug is a comprehensive resource for searching the association between drug sensitivity and RNA molecules at the expression level from the comprehensive
Fig. 3  UCHL1 knockdown inhibits cell migration and invasion in vitro. Immunohistochemical analysis (A) and western blot analysis (B) of interference results of cell lines with 10 mm LDN after 36 h of dosing. The migration (C) and invasion (D) of cells were detected by scratch and Transwell test (magnification × 400). *P < 0.05, **P < 0.01 compared to the control (E)
analysis of three large drug genome databases (GDSC, CellMiner, and CCLE). Spearman correlation coefficient showed that UCHL1 expression was negatively correlated with perezone, caracemide, bafetinib, and palbociclib and positively correlated with piperlongumine, gefitinib, Embelin, tipifarnib, phenformin, and bosutinib (Table 2). Therefore, perezone, caracemide, bafetinib, palbociclib, and other anti-tumor drugs may become potential therapeutic drugs for lung adenocarcinoma.

UCHL1 combined with other indicators can significantly improve the clinical diagnosis rate of lung adenocarcinoma

In TCGA transcriptome analysis, the area under the curve (AUC) of ALK, EGFR, TTF1, and UCHL1 were 0.476, 0.449, 0.499, and 0.755, respectively. Compared with ALK, EGFR, and TTF1, UCHL1 has higher predictive accuracy for lung adenocarcinoma. More importantly, the combination of ALK, EGFR, TTF1, and UCHL1 has the highest diagnostic efficiency (Fig. 5).

Discussion

Lung adenocarcinoma (LUAD) is one of the major subtypes of lung cancer that is associated with poor prognosis [14, 15]. At present, the literature reports that the occurrence and development of lung adenocarcinoma are closely related to circular RNA [16–18], microRNA [19, 20], and N6 methyladenosine [21]. Some scholars have also found some genes related to the differences and prognosis through biological information analysis [15, 22–24], for example, EGFR, KRAS, PIK3CA, STEAP1/2, HOXA11, and TCN1. In addition, some scholars analyze its application value in clinical diagnosis and treatment by constructing a new prognostic model [14, 21, 25, 26]. Therefore, the combination of bioinformatics technology to find possible diagnostic and prognostic markers of lung adenocarcinoma has become the key point.

It has been found that UCHL1 is highly expressed in different kinds of tumor cells [27]. In our study, the expression pattern of UCHL1 protein in normal and lung adenocarcinoma
tissues was further interpreted. The results showed that the expression of UCHL1 protein in lung adenocarcinoma was higher than that in normal tissues. In addition, the expression of UCHL1 was positively correlated with Ki-67, and it suggested that UCHL1 was related to cell proliferation. Consistent with previous bioinformatics analysis, silencing of UCHL1 is associated with tumor cell proliferation, migration, invasion, and poor prognosis of patients. The current research is focused on how to interfere with the regulation of UCHL1 in tumor cells. For instance, Parkinson disease uses UCHL1 as a substrate and as a regulator to accelerate the degradation of UCHL1 through the autophagy system [28]. In addition, the expression of UCHL1 is also regulated by lncRNA [29]. The control of UCHL1 translation can be achieved by the insertion of sineb2 repeats by lncRNA [30]. The downregulation of UCHL1 may be mediated by

**Table 2** Sensitivity analysis of UCHL1 to commonly used drugs in the treatment of lung cancer

| Compound     | RNA type | RNA molecule | Omics   | Source   | Spearman | P*       |
|--------------|----------|--------------|---------|----------|----------|----------|
| Perezone     | mRNA     | UCHL1        | Expression | CellMiner | −0.533803875 | 0.006029875 |
| Caracemide   | mRNA     | UCHL1        | Expression | CellMiner | −0.482980911 | 0.007064843 |
| Bafetinib    | mRNA     | UCHL1        | Expression | CellMiner | −0.479686548 | 0.01466201  |
| Palbociclib  | mRNA     | UCHL1        | Expression | CellMiner | −0.407997669 | 0.031646287 |
| Piperlongumine | mRNA    | UCHL1        | Expression | GDSC      | 0.08744003  | 0.03560008  |
| Gefitinib    | mRNA     | UCHL1        | Expression | GDSC      | 0.091381303 | 0.028871531 |
| Embelin      | mRNA     | UCHL1        | Expression | GDSC      | 0.097463539 | 0.047825308 |
| Tipifarnib   | mRNA     | UCHL1        | Expression | GDSC      | 0.110392871 | 0.019774916 |
| Phenformin   | mRNA     | UCHL1        | Expression | GDSC      | 0.110531447 | 0.001943254 |
| Bosutinib    | mRNA     | UCHL1        | Expression | GDSC      | 0.115226293 | 0.003381483 |

*P < 0.05

**Fig. 5** The impact of UCHL1 combined with common clinical indicators on the detection rate of lung adenocarcinoma through a bioinformatics database. AUC, area under the curve
UCHL1 has been proved to be able to induce several types of tumors [34]. In particular, UCHL1 promotes TGF-β signal transduction by acting on the TGF-β signaling pathway and Smad2 signaling pathway, thus inducing breast cancer cell metastasis [12]. UCHL1 gene silence limits the proliferation of endometrial cancer cells and delays the cell cycle [35]. UCHL1 promotes the growth of melanoma cells by activating the activity of protein kinase and activating the signal pathway [36]. In addition, the mechanism of UCHL1 in oncogenesis and development is still unclear. Our results indicate that the proliferation, migration, and invasion of lung adenocarcinoma cells are reduced with the silencing of UCHL1 gene, which further explains the carcinogenic role of UCHL1 in tumors. However, the specific mechanism of UCHL1 in lung adenocarcinoma is still unclear.

The regulatory effects of UCHL1 on autophagy and apoptosis have been reported [37, 38]. It has been reported that UCHL1 plays an important role in the occurrence and development of neurological diseases and other diseases [8]. LDN-induced downregulation of UCHL1 expression and upregulation of autophagy of oligodendrocytes lead to apoptosis [39]. UCHL1 can prevent autophagy (autophagic cell death) and promote cell proliferation by inhibiting apoptosis [40]. Furthermore, the effect of UCHL1 on apoptosis of lung adenocarcinoma cells has been shown for the first time.

In terms of the detection rate of lung adenocarcinoma indicators, we discovered UCHL1 could improve the detection rate of clinical lung adenocarcinoma and affect drug sensitivity. ALK, EGFR, and TTF1 are commonly used to detect lung adenocarcinoma. In order to test the detection efficiency of UCHL1 for lung adenocarcinoma in this study, we analyzed the detection rate of lung adenocarcinoma in a bioinformatics database combined with common clinical indicators. It was found that UCHL1 could distinguish cancer tissue from normal tissue. However, the combined diagnostic efficiency of UCHL1 and common indicators is excellent, suggesting that UCHL1 may have a high clinical application value [41]. Drug sensitivity analysis showed that perezone, caracemide, bafetinib, and palbociclib were negatively correlated with the expression of UCHL1, suggesting that these drugs have potential inhibitory effects on UCHL1. In vitro studies have reported that the natural product of perezone has an antitumor effect [42]. Caracemide was also used in the treatment of advanced renal cell carcinoma earlier [43]. In the past, bafetinib has been used in clinical trials in patients with leukemia and prostate cancer and in the treatment of leukemia [44]. Clinical studies in recent years also show that the use of palbociclib can prolong the overall survival of breast cancer patients [45].

Conclusion
In lung adenocarcinoma, UCHL1 combined with clinical lung tumor detection indicators improves the detection rate of lung adenocarcinoma, provides sensitive indicators for the early diagnosis of lung adenocarcinoma, and provides possible targets for the development of targeted drugs for lung adenocarcinoma.

Abbreviations
UCHL1: Ubiquitin C-terminal hydrolase L1; TMA: Tissue microarrays; TCGA: The Cancer Genome Atlas; IHC: Immunohistochemistry; PBS: Phosphate-buffered saline.

Acknowledgements
We would like to thank the team members for their contributions to this paper, and then, we will continue to work hard to do relevant research.

Authors’ contributions
Jianbo Yao, Abdusemer Reyimu, and Xiang Wang participated in the study design. Ao Sun, Xiang Wang, Zaxi Duoji, Wubi Zhou, Suxia Hu, and Song Liang statistically analyzed the data. The manuscript was drafted by Jianbo Yao, Jingjing Dai, Xiang Wang, and Xiaoguang Xu and revised by Xiang Wang and Xiaoguang Xu. The authors read and approved the final manuscript.

Funding
Special Project of Regional Science and Technology Collaborative Innovation of Naqu Science and Technology Bureau of Tibet, Grant No.:QYXTZX-NQ2022-03; Graduate Innovation Fund Project of Anhui University of Science and Technology in 2021, Grant No.:2021CX2128.

Availability of data and materials
The datasets supporting the conclusion of this article are included within the article.

Declarations
Ethics approval and consent to participate
All research experiments involving patient data were approved by the Ethics Committee (approval number: YX-2021-074-01).

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1 College of Life Sciences, Anhui Medical University, Hefei, Anhui 230032, People’s Republic of China. 2 Medical College, Anhui University of Science and Technology, Huainan, Anhui 232001, People’s Republic of China. 3 Class 11, Grade 2018, Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu 223300, People’s Republic of China. 4 Research Center of High Altitude Medicine, Naqu, Tibet, China, People’s Hospital of Naqu Affiliated to Dalian Medical University, Naqu, Tibet, China, People’s Hospital of Naqu Affiliated to Dalian Medical University, Naqu, Tibet, China.
1. Hutchinson BD, Shroff GS, Truong MT, et al. Spectrum of lung adenocarcinoma. Semin ultrasound CT MR. 2019;40(3):255–64.

2. Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018;9(2):117.

3. Wakejima R, Inamura K, Ninomiya H, et al. Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma. Pathol Int. 2020;70(2):72–83.

4. Hertzanu Y, Ye K. Computed tomography-guided percutaneous microwave ablation: a new weapon to treat ground-glass opacity-lung adenocarcinoma. J Cancer Res Ther. 2019;15(2):265–6.

5. Xu Y, Zhang C, Wang X, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell. 2020;182(1):245–61.e17.

6. Xu Y, Zheng M, Wang N, et al. Comprehensive study of surgical treated lung adenocarcinoma with ground glass nodule component. Med Sci Monit. 2019;25:8492–9.

7. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

8. Liu H, Povysheva N, Rose ME, et al. Role of UCHL1 in axonal injury and functional recovery after cerebral ischemia. Proc Natl Acad Sci U S A. 2019;116(10):4643–50.

9. Nakashima R, Goto Y, Koyasu S, et al. UCHL1-HIF-1 axis-mediated antioxidative property of cancer cells as a therapeutic target for radiosensitization. Sci Rep. 2017;7(1):6879.

10. Xu Y, Gao H, Hu Y, et al. High glucose-induced apoptosis and necroptosis in podocytes is regulated by UCHL1 via RIPK1/RIPK3 pathway. Exp Cell Res. 2019;382(2):11463.

11. Riva P, Ratti A, Venturin M. The long non-coding RNAs in neurodegenerative diseases: novel mechanisms of pathogenesis. Curr Alzheimer Res. 2016;13(11):1219–31.

12. Liu S, González-Prieto R, Zhang M, et al. Deubiquitinase activity profiling identifies UCHL1 as a candidate oncogene that promotes TGFB-induced breast cancer metastasis. Clin Cancer Res. 2020;26(6):1460–73.

13. Bi HL, Zhang YL, Yang J, et al. Inhibition of UCHL1 by LDN-57444 attenuates Ang II-induced atrial fibrillation in mice. Hypertens Res. 2020;43(3):168–77.

14. Xu Z, Wang S, Ren Z, et al. An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma. World J Surg Oncol. 2022;20(1):99.

15. Li H, Guo L, Cai Z. TCN1 is a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. World J Surg Oncol. 2022;20(1):83.

16. Xiao Y, Gu S, Yao W, et al. Circ_0047921 acts as the sponge of miR-1287-5p to stimulate lung cancer progression by regulating proliferation, migration, invasion, and glycolysis of lung cancer cells. World J Surg Oncol. 2022;20(1):108.

17. Chen Y, Wei S, Wang X, et al. Progress in research on the role of circular RNAs in lung cancer. World J Surg Oncol. 2018;16(1):215.

18. Liu X, Cheng Y, Wang Y, et al. Circular RNA circVAPA contributes to non-small-cell lung cancer progression via miR-342-5p-dependent regulation of ZEB2. World J Surg Oncol. 2021;19(1):335.

19. Zuo M, Yao L, Wen L, et al. The expression of miRNA-216b is negatively correlated with 18F-FDG uptake in non-small cell lung cancer. World J Surg Oncol. 2021;19(1):262.

20. Wang K, Chen M, Wu W. Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer. World J Surg Oncol. 2017;15(1):175.

21. Ja E, Ren N, Guo B, et al. Construction and validation of a novel prognostic model for lung squamous cell cancer based on N6-methyladenosine-related genes. World J Surg Oncol. 2022;20(1):59.

22. Li S, Li X. Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer. World J Surg Oncol. 2021;19(1):197.

23. Liu T, Niu X, Li Y, et al. Expression and prognostic analyses of the significance of STEAP1 and STEAP2 in lung cancer. World J Surg Oncol. 2022;20(1):96.

24. Zhang R, Zhang TT, Zhai GQ, et al. Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis. World J Surg Oncol. 2018;16(1):109.

25. Ding XL, Su YG, Yu L, et al. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC). World J Surg Oncol. 2022;20(1):54.

26. Li G, Wang G, Guo Y, et al. Development of a novel prognostic score combining clinicopathologic variables, gene expression, and mutation profiles for lung adenocarcinoma. World J Surg Oncol. 2020;18(1):249.

27. Hurst-Kennedy J, Chin LS, Li L. Ubiquitin C-terminal hydroxylation in tumorigenesis. Biochem Res Int. 2012;2012:123706.

28. Sala G, Marinig D, Arosio A, et al. Role of chaperone-mediated autophagy dysfunctions in the pathogenesis of Parkinson’s disease. Front Mol Neurosci. 2016:9:157.

29. Carrien C, Cimatti L, Biagioli M, et al. Long non-coding antisense RNA controls Uch1l translation through an embedded SINE2B repeat. Nature. 2012;491(7424):454–7.

30. Podbevešek P, Fasolo F, Bon C, et al. Structural determinants of the SINE B2 element embedded in the long non-coding RNA activator of translation AS Uchl1. Sci Rep. 2018;8(1):3189.

31. Zhang D, Han S, Wang S, et al. cPKCγ-mediated down-regulation of UCHL1 alleviates ischemic neuronal injuries by decreasing autophagy via ERK-mTOR pathway. J Cell Mol Med. 2017;21(2):3641–57.

32. Kobayashi E, Hwang D, Bhera-Malge A, et al. Inhibition of UCH-L1 deubiquitinating activity with two forms of LDN-57444 has anti-invasive effects in metastatic carcinoma cells. Int J Mol Sci. 2019;20(15):3733.

33. Fang Y, Shen X. Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications. Cancer Metastasis Rev. 2017;36(4):669–82.

34. Goto Y, Zeng L, Yeom CJ, et al. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating activity on HIF-1α. Nat Commun. 2015;6:6153.

35. Kwan SY, Au-Yeung CL, Yeung TL, et al. Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) promotes uterine serous cancer cell proliferation and cell cycle progression. Cancers (Basel). 2020;12(4):6153.

36. Costes S, Gurlo T, Rivera JF, et al. UCHL1 deficiency exacerbates human islet amyloid polypeptide toxicity in β-cells: evidence of interplay between the ubiquitin/proteasome system and autophagy. Autophagy. 2014;10(6):1004–14.

37. Pukaš K, Richter-Landsberg C. Inhibition of UCH-L1 deubiquitinating enzyme activity. Biochem Biophys Res Commun. 1996;218(1):57–60.

38. Kwan SY, Au-Yeung CL, Yeung TL, et al. Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) promotes uterine serous cancer cell proliferation and cell cycle progression. Cancers (Basel). 2020;12(1):118.

39. Pukaš K, Richter-Landsberg C. Inhibition of UCH-L1 deubiquitinating enzyme activity. Biochem Biophys Res Commun. 1996;218(1):57–60.
42. Hernandez-Rodriguez M, Mendoza SP, Macias PM, et al. In vitro and computational studies of natural products related to perezone as antineoplastic agents. Biochimie. 2020;171-172:158–69.
43. Witte RS, Hsieh P, Elson P, et al. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Invest New Drugs. 1996;14(4):409–13.
44. Santos FP, Kantarjian H, Cortes J, et al. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs. 2010;11(12):1450–65.
45. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–36.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.